Cadrenal Therapeutics, Inc. Common Stock (CVKD)
US — Healthcare Sector
Automate Your Wheel Strategy on CVKD
With Tiblio's Option Bot, you can configure your own wheel strategy including CVKD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CVKD
- Rev/Share 0.0
- Book/Share 3.315
- PB 3.1433
- Debt/Equity 0.0
- CurrentRatio 4.3174
- ROIC -2.1483
- MktCap 20492754.0
- FreeCF/Share -5.5185
- PFCF -2.0137
- PE -2.1379
- Debt/Assets 0.0
- DivYield 0
- ROE -1.7155
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Cadrenal Therapeutics, Inc. Common Stock (CVKD)
- IPO Date 2023-01-20
- Website https://www.cadrenal.com
- Industry Biotechnology
- CEO Quang X. Pham
- Employees 4
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.